Resources

This week I highlight innovation across the sector and call on pension funds to be mandated to support our industry.

The BioIndustry Association (BIA) has today published a report highlighting the rapid growth of the UK’s Deep Biotech sector.

In a world of uncertainty, Britain’s biotech future looks strong.

This week saw the publication of Engineering Biology Aspirations, the final output of Angela McLean’s Year of Engineering Biology. The report sets out an ambitious, forward-looking vision for the field, exploring how engineering biology could shape the future of everything from food and fashion to fuel and health.

The UK pavilion at SynBioBeta 2025 will unite leading UK engineering biology companies and ecosystem partners to highlight the UK’s world-class strengths in engineering biology.

It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.

A big raise as next generation biotech leaders gather, NHS England is abolished, and global trade disputes touch on our industry.

This week, BIA was invited by the Foreign Secretary to represent UK life sciences in Japan. In Parliament, we're championing a robust industrial strategy. Our new report provides the data and real life experience on womens’ leadership in our sector, while a former Board BIA member joins Duran Duran (sort of).

The UKHSA Conference 2025, delivered in partnership with the FPH, will explore the full breadth of UKHSA’s work; from science-driven research to effective policy implementation.

In this week’s blog, HM Treasury considers ISA changes to enable tax support for growth, a new engineering biology regulatory group gives the UK a strategic edge and a key MHRA webinar on ILAP is upcoming.

GitLife Biotech and Colorifix have partnered to enhance traceability and scalability in eco-friendly textile dyeing. The project is supported by Innovate UK.

In the fast-paced world of antibody research, time and efficiency are critical. To meet the growing demand for rapid, high-quality solutions, Biointron has launched a series of innovative small-scale antibody production packages under the RushMab™ brand.

Biointron and Cyagen have joined forces to create a breakthrough platform for discovering fully human antibodies.

RSSL has today announced that it has secured funding from Innovate UK, the UK’s national innovation agency, to establish the country’s first Novel Foods Expert Network for Regulatory Challenges (NFX UK).